<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799964</url>
  </required_header>
  <id_info>
    <org_study_id>ZHTQ2020001</org_study_id>
    <nct_id>NCT04799964</nct_id>
  </id_info>
  <brief_title>Flow Diverter(Ton-bridgeMT) For Treating Intracranial Aneurysms</brief_title>
  <official_title>The Efficacy and Safety Study of Flow Diverter(Ton-bridgeMT) on Endovascular Embolization of Intracranial Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhuhai Tonbridge Medical Tech. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhuhai Tonbridge Medical Tech. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, randomized, open, parallel positive control,&#xD;
      non-inferiority trail. The purpose of this study is assess the effectiveness and safety of&#xD;
      the flow diverter(Ton-bridgeMT) by comparing with the data obtained by Tubridge for the&#xD;
      endovascular treatment of intracranial aneurysms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Flow Diverter is an intracranial implant designed to be placed in a parent artery so as&#xD;
      to divert blood flow away from an aneurysm. This clinical trial is carried out in 14 research&#xD;
      centers. The subjects are randomly divided into the experimental group using flow&#xD;
      diverter(Ton-bridgeMT) and the control group using Tubridge at a ratio of 1:1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete occlusion rate of aneurysms</measure>
    <time_frame>360±45 days</time_frame>
    <description>The Raymond-Roy intracranial aneurysm occlusion classification was used to assess the rate of aneurysm occlusion at the time of primary endpoint assessment (12 months). Occlusion rates were reported as Class I: complete obliteration; Class II: residual neck; Class III: residual aneurysm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate of operation</measure>
    <time_frame>Intraoperation</time_frame>
    <description>Successful operation represents that the positioning of the test stent is accurate and effectively covers the aneurysm neck after intraoperative DSA(Digital subtraction angiography) examination of the vessels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete occlusion rate of aneurysms</measure>
    <time_frame>180±30days</time_frame>
    <description>The Raymond-Roy intracranial aneurysm occlusion classification was used to assess the occlusion rate of aneurysms, class I means complete occlusion of the aneurysms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subtotal occlusion rate</measure>
    <time_frame>360±45 days</time_frame>
    <description>Subtotal occlusion is defined as less than 10% of the contrast agent in the aneurysm.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The rate of stroke</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Stroke includes symptomatic ischemic stroke and hemorrhagic stroke.</description>
  </other_outcome>
  <other_outcome>
    <measure>The rate of the target vessel stenosis more that 50% and 100%</measure>
    <time_frame>360±45 days</time_frame>
    <description>The subjects receive DSA examination in 360 days at the 12 months follow-up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Procedure-related complication</measure>
    <time_frame>Intraoperation</time_frame>
    <description>Procedure-related complications include but are not limited to: incomplete stent opening, stent displacement, stent entry into the tumor, stent thrombosis, operation injury.</description>
  </other_outcome>
  <other_outcome>
    <measure>The rate of AE/SAE</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The definition of AE(Adverse Event) / SAE (Serious Adverse Event) refers to ISO 14155</description>
  </other_outcome>
  <other_outcome>
    <measure>Death rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Subjects who died from any cause would be counted.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flow diverter(Ton-bridgeMT, China)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tubridge(Microport, China)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Flow diverter(Ton-bridgeMT, China)</intervention_name>
    <description>The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introduction sheath. The stent and the delivery guide wire are pre-installed in the introduction sheath.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tubridge(Microport, China)</intervention_name>
    <description>Tubridge consists of a stent system and a microcatheter system. The stent system consists of a stent and a conveyor, the stent is self-expanding as well.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 80 years.&#xD;
&#xD;
          -  Subject has unruptured aneurysms located in Vertebral artery(VA) or Internal Carotid&#xD;
             Artery(ICA) diagnosed by DSA；&#xD;
&#xD;
          -  The neck width of the aneurysm ≥4 mm, the max diameter of the aneurysm body ≥10 mm.&#xD;
&#xD;
          -  The diameter of the target vessel is 2.0 to 6.5mm.&#xD;
&#xD;
          -  Subject or legal representative is able to understand the purpose of study, agrees to&#xD;
             comply with protocol requirements and has provided written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed as multiple aneurysms that can't be treated by single device or with&#xD;
             arteriovenous malformation.&#xD;
&#xD;
          -  Subject had a subarachnoid hemorrhage within 30 days prior to the enrollment date.&#xD;
&#xD;
          -  Modified Rankin Scale(mRS) score &gt;2&#xD;
&#xD;
          -  Platelet(PLT)&lt;60*10^9/L or International Normalized Ratio(INR)&gt;1.5&#xD;
&#xD;
          -  Heart, lung, liver, kidney failure or other serious diseases (such as brain tumors,&#xD;
             systemic infection, active disseminated intravascular coagulation, myocardial&#xD;
             infarction within 12 months before enrollment, history of severe mental illness);&#xD;
&#xD;
          -  Lesions judged by researchers that are not suitable for stent delivery and deployment&#xD;
             (such as severe stenosis of the tumor-bearing artery, too tortuous tumor-bearing&#xD;
             artery, and the stent cannot reach the lesion, etc.)&#xD;
&#xD;
          -  Have undergone major surgery within 30 days before enrollment or plan to undergo&#xD;
             surgery within 180 days after enrollment.&#xD;
&#xD;
          -  History of allergies to antiplatelet drugs, anticoagulants, anesthetics, contrast&#xD;
             agents.&#xD;
&#xD;
          -  History of allergies to platinum and tungsten.&#xD;
&#xD;
          -  Expected life &lt;12 months.&#xD;
&#xD;
          -  Female subjects who are pregnant or planning to become pregnant or lactate within the&#xD;
             study period.&#xD;
&#xD;
          -  Subject has participated in any other drug or medical device clinical trials in 1&#xD;
             month before signing informed consent .&#xD;
&#xD;
          -  Other circumstances judged by researchers that are not suitable for enrollment .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianmin Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danqing Shen</last_name>
    <phone>15858207851</phone>
    <email>dq.shen@ton-bridge.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dingrong Pan</last_name>
    <phone>18868106641</phone>
    <email>dr.pan@ton-bridge.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of USTC</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ge Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenfeng Feng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chuanzhi Duan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhuhai people's hospital</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guangsen Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The people's hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shengyong Lan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan provincial People's Hostpital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tianxiao Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Sheng Guan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenyuan Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fenghua Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hua Lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guohua Mao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianmin Liu</last_name>
      <phone>13901780638</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuxiang Gu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shu Wan</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 20, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

